Our study assessed the effects of the CYP3A4*22 allele and CYP3A5 expressor status in ticagrelor treated patients with a myocardial infarction, with respect to clinical endpoints and the side-effect dyspnea. Here, CYP3A5 is linked to myocardial infarction.